1. Home
  2. > Pharmaceutical
  3. > Therapy Market Trends
XOLAIR Marketed Drug Insight and Market Forecast ? 2032

XOLAIR Marketed Drug Insight and Market Forecast ? 2032

  • September 2022
  • 30 pages
  • ID: 6321487
  • Format: PDF
  • Delve Insight

Summary

Table of Contents

“XOLAIR Marketed Drug Insight and Market Forecast – 2032” report provides comprehensive insights about XOLAIR for Chronic Spontaneous Urticaria in seven major markets. A detailed picture of the XOLAIR for Chronic Spontaneous Urticaria in 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019 –2032 is provided in this report along with a detailed description of the XOLAIR for Chronic Spontaneous Urticaria. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the XOLAIR market forecast analysis for Chronic Spontaneous Urticaria in 7MM, SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in Chronic Spontaneous Urticaria.


Drug Summary

XOLAIR (omalizumab) is the only approved anti-IgE antibody indicated for moderate to severe persistent asthma in patients of 6 years and older with a positive skin test or in vitro reactivity to a perennial aeroallergen and symptoms that are inadequately controlled with inhaled corticosteroids, and chronic idiopathic urticaria in adults and adolescents of 12 years and older who remain symptomatic despite H1 antihistamine treatment.
Omalizumab is a recombinant DNA-derived humanized IgG1? monoclonal antibody that selectively binds to human immunoglobulin E (IgE); the antibody has a molecular weight of approximately 149 kilo Daltons. XOLAIR is produced by a Chinese hamster ovary (CHO) cell suspension culture in a nutrient medium that may contain the antibiotic gentamicin; gentamicin is not detectable in the final product. Omalizumab binds to IgE and lowers free IgE levels. Subsequently, IgE receptors (Fc?RI) on cells down-regulate. Also, the mechanism by which these effects of omalizumab result in an improvement of CIU symptoms is unknown.
Xolair is approved for the treatment of CSU in over 80 countries, including the European Union and chronic idiopathic urticaria (CIU), as it is known in the US and Canada. Xolair has over one million patient-years of exposure. Also, a liquid formulation of Xolair in prefilled syringes has been approved in the EU and more than 10 countries outside of the EU, including Canada, the US, and Australia. In the US, Novartis and Genentech worked together to develop and co-promote Xolair. Outside the US, Novartis markets Xolair and records all sales and related costs.
Dosage: 150 mg or 300 mg of XOLAIR is administered by subcutaneous injection every 4 weeks for the treatment of CIU. The dosing of XOLAIR in CIU patients is not dependent on serum IgE (free or total) level or body weight. XOLAIR injection is a clear to slightly opalescent and colorless-to-pale brownish-yellow solution available as 150 mg/mL in a single-dose prefilled syringe with a purple needle shield for CSU.
Administration: XOLAIR is available as a prefilled syringe and as a lyophilized powder in a vial for reconstitution. Both XOLAIR prefilled syringe and lyophilized powder should be administered by a healthcare professional. XOLAIR is administered by subcutaneous injection, which may take 5–10 s to administer. Also, more than one injection per site should not be administered.

Scope of the Report
The report provides insights into:
• A comprehensive product overview including the XOLAIR description, mechanism of action, dosage and administration, research and development activities in Chronic Spontaneous Urticaria.
• Elaborated details on XOLAIR regulatory milestones and other development activities have been provided in this report.
• The report also highlights the XOLAIR research and development activities in Chronic Spontaneous Urticaria across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around XOLAIR.
• The report contains forecasted sales of XOLAIR for Chronic Spontaneous Urticaria till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Chronic Spontaneous Urticaria.
• The report also features the SWOT analysis with analyst views for XOLAIR in Chronic Spontaneous Urticaria.

Methodology
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis ’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

XOLAIR Analytical Perspective

• In-depth XOLAIR Market Assessment

This report provides a detailed market assessment of XOLAIR for Chronic Spontaneous Urticaria in seven major markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2022 to 2032.

• XOLAIR Clinical Assessment

The report provides the clinical trials information of XOLAIR for Chronic Spontaneous Urticaria covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights
• In the coming years, the market scenario for Chronic Spontaneous Urticaria is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence XOLAIR dominance.
• Other emerging products for Chronic Spontaneous Urticaria are expected to give tough market competition to XOLAIR and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of XOLAIR in Chronic Spontaneous Urticaria.
• Our in-depth analysis of the forecasted sales data of XOLAIR from 2022 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the XOLAIR in Chronic Spontaneous Urticaria.

Key Questions
• What is the product type, route of administration and mechanism of action of XOLAIR?
• What is the clinical trial status of the study related to XOLAIR in Chronic Spontaneous Urticaria and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the XOLAIR development?
• What are the key designations that have been granted to XOLAIR for Chronic Spontaneous Urticaria?
• What is the forecasted market scenario of XOLAIR for Chronic Spontaneous Urticaria?
• What are the forecasted sales of XOLAIR in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to XOLAIR for Chronic Spontaneous Urticaria?
• Which are the late-stage emerging therapies under development for the treatment of Chronic Spontaneous Urticaria?

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Grace helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at [email protected] to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - [email protected] or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Montelukast Sodium Market Growth Opportunities, 2023 - Market Insights, Mega Trends, Companies, and Forecasts to 2030

  • $ 4880
  • November 2022
  • 170 pages

Montelukast Sodium market outlook The Montelukast Sodium Market analysis and outlook report presents forecasts by Type, Application, country, and companies. The Montelukast Sodium market outlook report ...

  • World
  • Europe
  • Respiratory Treatment
  • Industry analysis

Global Bronchodilators Industry $ 5600 October 2022


ref:plp2022

Reportlinker.com © Copyright 2022. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on